Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients...
-
Upload
vincent-horton -
Category
Documents
-
view
216 -
download
0
Transcript of Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients...
Cyclosporine A reduces infarct sizeand has no detrimental effect of LV
remodeling in STEMI patients
Michel OvizeCardiology Hospital and Inserm U886
Lyon University, France
Previous work by Piot et al. (NEJM 2008)Objective: determine whether cyclosporine A can reduce infarct size in STEMI patients
Direct stenting
Coronary artery occlusion Reperfusion
t0t-10 min
Cyclosporine A (or saline)(2.5 mg/kg, IV bolus)
Day 1-3CK / TnI release
Day 5MRI
Infarct size
STEMI < 12 hrsPCI treatment
LAD TIMI flow grade 0-1No visible collaterals
0
1000
2000
3000
4000
5000
6000 CK release
Adm.
4h 8h 12h
16h
20h
24h
30h
36h
42h
48h
54h
60h
66h
72h
ControlCsA
(UI/
L)
0
50
100
150
200
250
Control
CsA
Adm.
4h 8h 12h
16h
20h
24h
30h
36h
42h
48h
54h
60h
66h
72h
TnI release
0
1.4.105
10 30 50 70ACS (%)
AU
C (
arb
itra
ry u
nit
s) 1.2.105
1.0.105
0.8.105
0.6.105
0.4.105
0.2.105
controlCsA
CK release
00 20 40 60
1.2.105
1.0.105
0.8.105
0.6.105
0.4.105
0.2.105
AU
C (
arb
itra
ry u
nit
s)
TnI release
Reduction of cardiac enzymes release by cyclosporine APiot et al. NEJM 2008
0control cyclosporine
area
of
hyp
eren
han
cem
ent
(g)
10
20
30
40
50
60
70
120
*
MRI infarct size (day 5)
Piot et al. NEJM 2008;359:473-81
Mewton et al. J Am Coll Cardiol 2010;55:1200–5
Rationale• CsA can reduce infarct size in STEMI patients. It
is therefore expected that this protective effect may be associated with a reduced adverse LV remodeling
• However, experimental evidence indicates that CsA, via anti-hypertrophic mechanisms, may favor an adverse remodeling response of the LV after STEMI
• We then assessed LV volumes and wall thickness by MRI at 5 days and 6 months after AMI in a population of patients that had received CsA as an adjunct to PCI revascularization
PCI
Coronary artery occlusion Reperfusion
t0t-10 min
Cyclosporine A or saline
Day 5 MRI 6 Month MRI
Follow up CMR at 6 months post-MI
Mewton et al. JACC 2010
*
Control Cyclosporine
Mewton et al. (JACC 2010)
Cyclosporine in acute myocardial infarction
PCI
Coronary artery occlusion Reperfusion
t0t-10 min
Cyclosporine A
Day 5 MRI 6 Month MRI
Follow up CMR at 6 months post-MI
Mewton et al. J Am Coll Cardiol 2010;55:1200–5
There was a significant correlation between left ventricular end-diastolic volume(LVEDV) and infarct size at 6 months (r2=0.40; p<0.05) in the whole group of patients
There was a significant correlation between left ventricular end-systolic volume (LVESV)and infarct size at 6 months (r2=0.66; p<0.05) in the whole group of patients
There was a significant correlation between left ventricular ejection fraction (LVEF)and infarct size at 6 months (r2=0.72; p<0.05) in both groups of patients
*
MRI at 6 months after cyclosporine-treated MI
*
Mewton et al. (JACC 2010)
Conclusion
• Cyclosporine used at the moment of acute myocardial infarction reperfusion reduces infarct size and does not have a detrimental effect of LV remodeling.
• These results obtained from a limited population of patients must be confirmed by large-scale trials
Michel OVIZE, MD, PhD